Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-05-10
2011-05-10
Crane, Lawrence E (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S557000, C514S576000
Reexamination Certificate
active
07939561
ABSTRACT:
Provided are rapidly bioavailable solid oral dosage forms of acute pain medications, and moisture resistant packaging that enables the formulation of such rapidly bioavailable tablet dosage forms. Also provided is packaging that discourages the use of rapidly bioavailable acute pain medications for off-label chronic pain treatment, and that allows such dosage forms to be manufactured and stored for prolonged periods of time.
REFERENCES:
patent: 3558690 (1971-01-01), Sallmann et al.
patent: 4689218 (1987-08-01), Gazzaniga et al.
patent: 5458879 (1995-10-01), Singh et al.
patent: 6974595 (2005-12-01), Reiner et al.
patent: 7687542 (2010-03-01), Reiner et al.
patent: 7700125 (2010-04-01), Reiner et al.
patent: 2005/0147671 (2005-07-01), Reiner et al.
patent: 2005/0214363 (2005-09-01), Reiner et al.
patent: 2005/0215643 (2005-09-01), Reiner et al.
patent: 2006/0013896 (2006-01-01), Reiner et al.
patent: 2131515 (1994-09-01), None
patent: 0 418 043 (1990-12-01), None
patent: 0 466 640 (1992-01-01), None
patent: A-2 401 547 (2004-11-01), None
patent: WO 94/03160 (1994-02-01), None
patent: WO 96/14839 (1996-05-01), None
patent: 97/44023 (1997-05-01), None
Gennaro et al. (eds.), Remington's Pharmaceutical Science, 18th Edition, Mack Publishing Co., Easton, PA, 1990, only p. 1637 supplied.
Gennaro et al. (eds.), Remington's Pharmaceutical Science, 18th Edition, Mack Publishing Co., Easton, PA, 1990, Chapters 75-92.
Brizuela et al., “Drug Information,” Chapter 7 in Remington's Pharmaceutical Science, 18th Edition, Mack Publishing Co., Gennaro et al. (eds.), Easton, PA, 1990, only pp. 49-59 supplied.
McNeely W et al: “Ficlofenac-potassium in migraine: a review.” Drugs Jun. 1999, vol. 57, No. 6, Jun. 1999, pp. 991-1003, XP009077504.
Database Internet [Online] Feb. 2005, Novartis Pharma: “Voltaren Dispers” XP002434112 retrieved from Internet accession No. http://www.fachinfo.de/pdf/00/59/005941.pdf.
Henry, D., et al; “Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs; results of a collaborative meta-analysis”; BMJ; vol. 312, pp. 1563-1566, (1996).
Walker A.M.; “Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory dugs”; Arthritis and Rheumatism. vol. 40, No. 2, pp. 201-108 (1997).
Gutthann, S.P., et al; “Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure”; Arch. Intern. Med., vol. 156, pp. 2433-2439, (1996).
Amidon, G.L., et al; “A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivi bioavailability”; Pharm. Research, vol. 12, No. 3, pp. 413-420, (1995).
U.S. Appl. No. 11/132,023, filed May 18, 2005, Reiner, et al.
U.S. Appl. No. 11/132,024, filed May 18, 2005, Reiner, et al.
U.S. Appl. No. 11/180,996, filed Jul. 13, 2005, Reiner, et al.
U.S. Appl. No. 11/030,537, filed Jan. 5, 2005, Reiner, et al.
U.S. Appl. No. 11/351,611, filed Feb. 10, 2006, Reiner, et al.
U.S. Appl. No. 11/455,120, filed Jun. 16, 2006, Reiner, et al.
U.S. Appl. No. 11/349,008, filed Feb. 7, 2006, Reiner, et al.
Neuvonen, P.J., “The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac”; Br. J. Clin. Pharmac. vol. 31, pp. 263-266, (1991).
Neuvonen, P.J., et al; “Enhancement of drug absorption by antacids”; Clin. Pharmacokinet. 27 (2): pp. 120-128, (1994).
Neuvonen, P.J., et al; “Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids”; Eur. J. Clin. Pharmacol, 35: pp. 495-501, (1988).
Derendorf, H., et al; “Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate”; Eur. J. Clin. Pharmacol.., 31:363-365 (1986).
Terhaag, B., et al; “Bioavailability of a new effervescent tablet of diclofenac”; Int. J. Clin. Pharmacol. Ther., 38:546-551 (2000).
Lotsch, J. et al; “Popluation pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model”; Phamaceutical Research, vol. 17, No. 1, pp. 77-84, (2000).
Marzo, A., et al; “Pharmacokinetics of Diclofenac after oral administration of its potassium salt in sachet an tabled formulations”; Arzneim. Forsch., 50:43-47 (2000).
Reiner, V., et al; “Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt”; Arzneim. Forsch., 51-885-890 (2001).
Fourtillan, J.B. et al; “Etude pharmacocinetique du piroxicam chez I'homme sain”; Therapie, vol. 38, pp. 163-170, (1983).
Brogden, R.N., et al; “Diclofenac sodium: A review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying orgin”; Drugs, 20: pp. 24-48, (1980).
Macia, M.A., et al: “Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks”; Int. J. Clin Pharmacol. Ther., 33:333-339 (1995).
Bettini, R., et al; “Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets”, S.T.P. Pharma Sciences 10 (4) pp. 335-339, (2000).
Henrikson, P.A., et al; Absorption and effect of diclofenac sodium after surgical removal of a lower wisdom tooth; Curr. Ther. Res., 31:30-36 (1982).
Degen, P.H., et al; “Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients”; Xenobiotica, 18:1449-1455 (1988).
Maggi, C.A., et al; “Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man”; Eur. J. Clin. Pharmacol., 38:207-208 (1990).
Mendes, G.B.B., et al; “Comparative bioavailability of two suspension formulations of potassium diclofenac in healthy male volunteers”; Int. J. Clin. Pharmacol. Thr., 32:131-135 (1994).
Crook, P.R., et al; “The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease”; Eur. J. Clin. Pharmacol., 21:331-334 (1982).
Willis. J.V., et al; “The pharmacokinetics of diclofenac sodium following intravenous and oral administration”; Eur. J. Clin. Pharmacol., 16:405-410 (1979).
Willis, J.V., et al; “The influence of food on the absorption of diclofenac after single and multiple oral doses”; Eur. J. Clin. Pharmacol., 19:33-37 (1981).
Reiss, W., et al; “Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren” Scand. J. Reumatol., Suppl. 22:17-29 (1978).
Physicians' Desk Reference; Novartis Pharmaceutical Corp., pp. 1830-1832 (2000).
Bakshi, R., et al; A double-blind, Placebo-controlled trial comparing the analgesic efficacy of two formulations of Diclofenac in postoperative dental pain; Current Therapeutic Research vol. 52, No. 3, pp. 435-442 Sep. 1992.
Dahlöf, C., et al; Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine; Cephalalagia 13, pp. 20-26 (1993).
McNeely, W., et al; Diclofenac-Potassium in Migraine: A Review; Drugs; 57; pp. 991-1003 (1999).
Mehlisch, D.R., et al; Single-dose therapy with Diclofenac potassium, aspirin, or placebo following dental impaction surgery, Today's Therapeutic Trends 12; (Suppl. 1) pp. 15-31 (1995).
The Diclofenac-K/Sumatriptan Migrain Study Group; Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo; Cephalalgia 19, pp. 232-240 (1999).
Ridgway, D.; Analgesics for Acute Pain, Meeting the United States Food and Drug Administration's Requirements for Proof of Efficacy, Clin J. Pain vol. 20, No. 3, May/June pp. 123-132 (2004).
Diener, H-C, et al; Efficacy and tolerability of Diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with Diclofenac potassium ta
Maichle William R.
Reiner Alberto
Reiner Giorgio
Schellenger Norman D.
Whatley, Jr. Carl L.
APR Applied Pharma Research S.A.
Arnall Golden & Gregory LLP
Crane Lawrence E
Sullivan Clark G.
LandOfFree
Blister packaging for acute pain regimens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blister packaging for acute pain regimens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blister packaging for acute pain regimens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2708128